Research graph
References from Evaluating the safety of daptomycin coadministered with statin medications. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
10.1093/cid/ciq146 · 2011 · External reference
Effect of statin coadministration on the risk of daptomycin-associated myopathy
10.1093/cid/ciy287 · 2018 · External reference
Risk of muscle toxicity events for daptomycin with and without statins: analysis of the Japanese Adverse Event Report database
10.1111/bcpt.13618 · 2021 · External reference
A retrospective multisite case-control series of concomitant use of daptomycin and statins and the effect on creatine phosphokinase
10.1093/ofid/ofz444 · 2019 · External reference
Daptomycin-induced hyperkalemia as an early sign of rhabdomyolysis in a diabetic patient
2020 · External reference
Effects of statins on skeletal muscle: a perspective for physical therapists
10.2522/ptj.20090251 · 2010 · External reference
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
10.1016/j.jacl.2022.05.068 · 2022 · External reference
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
10.1056/nejmoa050461 · 2005 · External reference
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
2023 · External reference
Prevalence, associated risk factors, and adverse cardiovascular outcomes of statins discontinuation: a systematic review
10.1002/pds.5879 · 2024 · External reference
Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France
10.1093/eurheartj/ehz458 · 2019 · External reference
